Natus Medical Incorporated (NTUS) News

Natus Medical Incorporated (NTUS): $24.58

-0.85 (-3.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter NTUS News Items

NTUS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest NTUS News From Around the Web

Below are the latest news stories about Natus Medical Inc that investors may wish to consider to help them evaluate NTUS as an investment opportunity.

Bryant M. Moore, Ph.D. and Eric J. Guerin Appointed to Natus Board of Directors

PLEASANTON, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced the appointments of Bryant M. Moore, Ph.D. and Eric J. Guerin to the Company's Board of Directors. With these appointments, the Natus Board will be expanded to eight members. “We are pleased to welcome

Yahoo | August 18, 2021

Natus Medical Announces Second Quarter 2021 Financial Results

Q2-2021 Key ResultsRevenue (millions)$116.0 • Revenue increased 37% compared to Q2 2020• Generated $19.4 million in operating cash flow• GAAP and Non-GAAP EPS increased by $0.36 and $0.42, respectively compared to Q2 2020GAAP EPS$0.10 Non-GAAP EPS$0.29 PLEASANTON, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system

Yahoo | August 5, 2021

First Case Performed Using Natus XactTrode™ Subdural Electrodes

Launch to US Market of XactTrodes for Epilepsy Surgical MonitoringPLEASANTON, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, is pleased to announce the completion of the first successfully performed clinical case using Natus’ newly launched XactTrode™ family of platinum subdu

Yahoo | August 3, 2021

Natus Medical to Hold 2021 Second Quarter Financial Results Conference Call on August 6th

PLEASANTON, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 second quarter financial results after the close of the market on Thursday, August 5th. Natus management will host a conference call on Friday, August 6th at 8:

Yahoo | July 1, 2021

Natus Chairperson Dr. Barbara Paul Retires; Board Elects Current Board Member Joshua Levine as Chairperson

PLEASANTON, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced Dr. Barbara Paul, the Chairperson of the Board of Directors will retire from the Board effective June 30, 2021. The Board has elected independent director Joshua Levine who has served on the Natus boar

Yahoo | June 28, 2021

Natus Medical Announces First Quarter 2021 Financial Results

Q1-2021 Key ResultsRevenue (millions)$114.9 • Revenue increased 5% compared to Q1 2020 and in-line with Q1 2019GAAP EPS$0.07 • Generated $24.7 million in operating cash flowNon-GAAP EPS$0.16 • GAAP and Non-GAAP EPS increased by $0.18 and $0.12, respectively compared to Q1 2020 PLEASANTON, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced financial results for the three months ended March 31, 2021. For the first quarter ended March 31, 2021, the Company reported revenue of $114.9 million, an increase of 5.1% compared to $109.4 million reported for the firs...

Yahoo | May 6, 2021

Natus Medical, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Natus Medical, Inc. (NASDAQ:NTUS) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern Time.

Yahoo | May 6, 2021

Natus Medical to Hold 2021 First Quarter Financial Results Conference Call on May 6th

PLEASANTON, Calif., April 01, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 first quarter financial results after the close of the market on Thursday, May 6th. Natus management will host a conference call the same day beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 for domestic callers, or 1-508-637-5658 for international callers, and entering reservation code 5608595. A ...

Yahoo | April 1, 2021

Natus Medical Announces Fourth Quarter 2020 Financial Results

Q4-2020 Key ResultsRevenue (millions)$118.7 Revenue increased 15.5% compared to 3rd quarterGenerated $16.3 million in operating cash flowReduced debt by $10.0 million during the quarterAcquired Babybe GmbH during the quarter GAAP EPS$0.15 Non-GAAP EPS$0.39 PLEASANTON, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced financial results for the three months and full year ended December 31, 2020. For the fourth quarter ended December 31, 2020, the Company reported revenue of $118.7 million, a decline of 9.7% compared to $131.4 million reported for the fourt...

Yahoo | February 25, 2021

15 Best Small-Cap Healthcare Stocks to Buy

In this article, we present the 15 Best Small-Cap Healthcare Stocks to Buy. If you’re in a hurry, click to skip ahead and see the 5 Best Small-Cap Healthcare Stocks to Buy. The term small cap can be used to define established companies with a small market capitalization ranging anywhere between $300 million and $2 […]

Yahoo | February 14, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.9442 seconds.